Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tamoxifen resistance and CYP2D6 copy numbers in breast cancer patients.

Asian Pacific journal of cancer prevention : APJCP - 1 Jan 2012

Motamedi Sahar, Majidzadeh Keivan, Mazaheri Mahta, Anbiaie Robab, Mortazavizadeh Seyed Mohammad Reza, Esmaeili Rezvan

Abstract excerpt

BACKGROUND: Breast cancer accounts about one million from total annual ten million new diagnosed cases of neoplasia worldwide and is the main cause of death due to cancer in women. Tamoxifen is the most popular selective estrogen receptor modulator used in anti estrogen treatments. Tamoxifen must be converted into its metabolite endoxifen for biologic effects; this conversion process is catalysed by highly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Case-Control Studies

Share to Cytochrome P-450 CYP2D6

Share to DNA Copy Number Variations

Share to Genotype

Share to Tamoxifen

Source

Identifiers

PMID: 23464412
DOI: 10.7314/apjcp.2012.13.12.6101

Genes

ALB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tamoxifen resistance and CYP2D6 copy numbers in breast cancer patients.PMID 23464412Read ↗

Clinical Trial: CYP2D6 Related Dose Escalation of Tamoxifen in Breast Cancer Patients With Iranian Ethnic Background Resulted in Increased Concentrations of Tamoxifen and Its MetabolitesSemantic proximity Read ↗

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.Semantic proximity Read ↗

Polymorphism of the CYP2D6 gene in women with breast cancer treated with tamoxifen.Semantic proximity Read ↗

Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.Semantic proximity Read ↗

Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.Semantic proximity Read ↗

Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen TherapySemantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

Pharmacogenetics and Pharmacokinetics of Tamoxifen in a Zimbabwean breast cancer cohortSemantic proximity Read ↗

Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.Semantic proximity Read ↗

The effect analysis of CYP2D6 gene polymorphism in the toremifene and tamoxifen treatment in patient with breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.